Cargando…
A single immunization with cellular vaccine confers dual protection against SARS‐CoV‐2 and cancer
The efficacy of current coronavirus disease 2019 (COVID‐19) vaccines has been demonstrated; however, emerging evidence suggests insufficient protection in certain immunocompromised cancer patients. We previously developed a cell‐based anti‐cancer vaccine platform involving artificial adjuvant vector...
Autores principales: | Shimizu, Kanako, Ueda, Shogo, Kawamura, Masami, Satoh, Mikiko, Fujii, Shin‐ichiro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9348309/ https://www.ncbi.nlm.nih.gov/pubmed/35598170 http://dx.doi.org/10.1111/cas.15434 |
Ejemplares similares
-
Combination of cancer vaccine with CD122-biased IL-2/anti-IL-2 Ab complex shapes the stem-like effector NK and CD8(+) T cells against tumor
por: Shimizu, Kanako, et al.
Publicado: (2023) -
Cancer immunotherapy using artificial adjuvant vector cells to deliver NY‐ESO‐1 antigen to dendritic cells in situ
por: Fujii, Shin‐ichiro, et al.
Publicado: (2022) -
In vivo dendritic cell targeting cellular vaccine induces CD4(+) Tfh cell-dependent antibody against influenza virus
por: Yamasaki, Satoru, et al.
Publicado: (2016) -
Optimal therapeutic strategy using antigen‐containing liposomes selectively delivered to antigen‐presenting cells
por: Iyoda, Tomonori, et al.
Publicado: (2019) -
Natural Killer T and Natural Killer Cell-Based Immunotherapy Strategies Targeting Cancer
por: Iyoda, Tomonori, et al.
Publicado: (2023)